In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Genzyme

http://www.genzyme.com

Latest From Sanofi Genzyme

Celltrion Allies With 180 Life Sciences On Repurposing Biosimilars

Celltrion has struck a deal with 180 Life Sciences to supply anti-TNF products to support the company’s work in pursuing new indications for off-patent biologics.

Deals Biosimilars

Generic Drugs: ‘Competitive’ Exclusivity Benefited Few Sponsors But Is Increasingly Popular

The six months of additional exclusivity from US FDA’s CGT program appears to have kept some generic sponsors from the market, and didn’t even prompt others to enter quickly, but use of the competitive generic exclusivity program continues to grow.

Generic Drugs Intellectual Property

Atavistik Bio Raises $60m For Metabolic Disease, Cancer Drug Discovery

The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.

Financing Innovation

Sanofi Challenges EMA’s Refusal Of New Active Substance Status For Nexviadyme

Sanofi wants the European Medicines Agency to re-examine its opinion that the company’s drug for Pompe disease does not qualify as a new active substance.

Europe Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AnorMED
    • Bioenvision
    • ILEX Oncology, Inc.
    • Sangstat Medical Corporation
    • Genzyme Corporation
UsernamePublicRestriction

Register